Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

CERTEST BIOTEC

Certest Biotec, S.L. develops and manufactures IVD products in the human clinical testing field, including rapid test... read more Featured Products: More products

Download Mobile App





Certest Present Latest Innovations in Diagnosis of Infectious Diseases

By LabMedica International staff writers
Posted on 22 Jul 2023
Print article
Image: The VIASURE Complete Solution provides a perfect combination of products and tools for laboratories (Photo courtesy of CerTest)
Image: The VIASURE Complete Solution provides a perfect combination of products and tools for laboratories (Photo courtesy of CerTest)

CerTest Biotec (Zaragoza, Spain), a company specializing in the development, manufacturing, and commercialization of solutions for the diagnosis of infectious diseases, is participating in AACC 2023. Recognized as one of the largest global gatherings for the diagnostics sector, the annual AACC exhibition offers attendees the opportunity to explore the latest trends, technologies, and advances in the field of clinical diagnostics. With the participation of over 800 exhibitors, numerous experts, and industry leaders, this exhibition has established itself as a key meeting point for networking, knowledge exchange, and discovering the latest innovations in the sector.

Certest is taking advantage of this important platform to present its latest innovations in the diagnosis of infectious diseases, with a clear focus on the flexibility of its products and processes, as well as the speed and accuracy of results. Certest is showcasing a wide range of solutions, including rapid tests, RT-PCR tests (based on molecular biology), chemiluminescence (CLIA), and turbidimetry, in addition to raw materials for diagnostic product manufacturers.

One of the highlights of Certest’s participation in the exhibition is the demonstration of the VIASURE Complete System. This integrated system offers a comprehensive solution for the diagnosis of infectious diseases, providing fast and reliable results that improve workflow in the diagnostic laboratory. Thanks to its advanced technology, VIASURE solutions deliver exceptional performance and increased efficiency in diagnostic laboratories. In addition to product and solution showcases, Certest is also involved in research, presenting up to 14 publications in the form of posters, reflecting the latest studies conducted by the company, mainly in the field of molecular biology.

Related Links:
CerTest Biotec 

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Amoebiasis Test
ELI.H.A Amoeba
New
Silver Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.